| Autor: |
Tofte, N. Lindhardt, M. Adamova, K. Bakker, S.J.L. Beige, J. Beulens, J.W.J. Birkenfeld, A.L. Currie, G. Delles, C. Dimos, I. Francová, L. Frimodt-Møller, M. Girman, P. Göke, R. Havrdova, T. Heerspink, H.J.L. Kooy, A. Laverman, G.D. Mischak, H. Navis, G. Nijpels, G. Noutsou, M. Ortiz, A. Parvanova, A. Persson, F. Petrie, J.R. Ruggenenti, P.L. Rutters, F. Rychlík, I. Siwy, J. Spasovski, G. Speeckaert, M. Trillini, M. Zürbig, P. von der Leyen, H. Rossing, P. Zimmermann, S. Rädisch, B. Hävemeier, A. Busmann, A. Wittkop, U. Neuhaus, B. Ax-Smolarski, R. Zieglschmid, V. Bollweber, E. Wölk, H. Curovic, V.R. Tougaard, N.H. Eickhoff, M.K. Pilemann-Lyberg, S. Winther, S.A. Rosenlund, S.V. Hansen, T.W. von Scholten, B.J. Hansen, C.S. Zobel, E.H. Laursen, J.C. Theilade, S. Jelstrup, L. Juhl, T.R. Riis, D. Hermann, J.A. Lundgaard, A.G. Halkjær, M.L.D. Aabo, L. Frost Lerche, T. Lajer, M. Stefansen, R.J. Campbell, M.A. Durban, A. Raad, J. Prigge, M. Schiemann, M. Wilson, R. Kean, S. Douglas, E. Surtees, P. Gant, C. Yeung, S.M.H. Hagedoorn, I. Flynn, J. Galloway, J. Brooksbank, K. Aparicio, C. Iliev, I.P. Nones, F. Lo Bue, F. Melacini, D. Cugini, D. Prandini, S. Lecchi, V. Yakymchuk, S. Gherardi, G. Villa, A. Villa, D. Gaspari, F. Cannata, A.N. Ferrari, S. Stucchi, N. Albrechtová, Š. Eldeik, E. Amanaki, R. Fernandez-Fernandez, B. Sanchez-Rodriguez, J. Vázquez, C. Sanz, A.B. Sanchez-Niño, M.D. Ramos, A.M. Gonzalo, M.Á. Schmidt, U. Selim, G. Gjorgovski, T. Stratrova, S.S. Stojceva-Taneva, O. Schutten-Westerneng, P. Wierbos, B. Huvers, F. De Bruin, A.K. Lapauw, B. de Man, E. Rokegem, K. Inion, S. Kreutzmann, K. Dewettinck, I. Boukens-de Graaf, C. Clerc-de Jong, F. Entius, J. Nannings, M. van Steenderen, S. Petry, F.W. Kilic, C. PRIORITY investigators |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Popis: |
Background: Microalbuminuria is an early sign of kidney disease in people with diabetes and indicates increased risk of cardiovascular disease. We tested whether a urinary proteomic risk classifier (CKD273) score was associated with development of microalbuminuria and whether progression to microalbuminuria could be prevented with the mineralocorticoid receptor antagonist spironolactone. Methods: In this multicentre, prospective, observational study with embedded randomised controlled trial (PRIORITY), we recruited people with type 2 diabetes, normal urinary albumin excretion, and preserved renal function from 15 specialist centres in ten European countries. All participants (observational cohort) were tested with the CKD273 classifier and classified as high risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants who were classified as high risk were entered into a randomised controlled trial and randomly assigned (1:1), by use of an interactive web-response system, to receive spironolactone 25 mg once daily or matched placebo (trial cohort). The primary endpoint was development of confirmed microalbuminuria in all individuals with available data (observational cohort). Secondary endpoints included reduction in incidence of microalbuminuria with spironolactone (trial cohort, intention-to-treat population) and association between CKD273 risk score and measures of impaired renal function based on estimated glomerular filtration rate (eGFR; observational cohort). Adverse events (particularly gynaecomastia and hyperkalaemia) and serious adverse events were recorded for the intention-to-treat population (trial cohort). This study is registered with the EU Clinical Trials Register (EudraCT 20120-004523-4) and ClinicalTrials.gov (NCT02040441) and is completed. Findings: Between March 25, 2014, and Sept 30, 2018, we enrolled and followed-up 1775 participants (observational cohort), 1559 (88%) of 1775 participants had a low-risk urinary proteomic pattern and 216 (12%) had a high-risk pattern, of whom 209 were included in the trial cohort and assigned to spironolactone (n=102) or placebo (n=107). The overall median follow-up time was 2·51 years (IQR 2·0–3·0). Progression to microalbuminuria was seen in 61 (28%) of 216 high-risk participants and 139 (9%) of 1559 low-risk participants (hazard ratio [HR] 2·48, 95% CI 1·80–3·42; p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
